Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) - Results from a Prospective Multicenter Phase 2 Clinical Trial

被引：3
|
作者：
Shustov, Andrei R. [1 ,2 ]
Shinohara, Michi M. [3 ]
Dakhil, Shaker R. [4 ]
Bhat, Gajanan [5 ]
Zain, Jasmine M. [6 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Univ Washington, Div Hematol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Dermatol, Seattle, WA 98195 USA
[4] Canc Ctr Kansas, Wichita, KS USA
[5] Spectrum Pharmaceut Inc, Irvine, CA USA
[6] City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-119684
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2910
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas
    Song, Yuqin
    Li, Zengjun
    Wu, Huijing
    Jin, Jie
    Zhou, Hui
    Zhou, Keshu
    Zhang, Liling
    Peng, Zhigang
    Zhang, Zhiye
    Cen, Hong
    Jia, Youchao
    Shuang, Yuerong
    Li, Zhiming
    Yang, Haiyan
    Zou, Liqun
    Li, Zhifeng
    Zhang, Zhihui
    Li, Junmin
    Cao, Junning
    Qiu, Lugui
    Wu, Shaojie
    Gong, Tiejun
    Xu, Xiaohong
    Wang, Zhen
    Zhu, Jun
    BLOOD, 2023, 142
  • [22] HIGH-MALIGNANT PERIPHERAL T-CELL-LYMPHOMAS - TREATMENT RESULTS OF A RETROSPECTIVE OPEN MULTICENTER TRIAL
    KUSE, R
    LENNERT, K
    CALAVREZOS, A
    TIEMANN, M
    ENGELHARD, M
    ONKOLOGIE, 1991, 14 (03): : 268 - 271
  • [23] Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial
    Damaj, Gandhi
    Gressin, Remy
    Bouabdallah, Krimo
    Cartron, Guillaume
    Choufi, Bachra
    Gyan, Emmanuel
    Banos, Anne
    Jaccard, Arnaud
    Park, Sophie
    Tournilhac, Olivier
    Schiano-de Collela, Jean-Marc
    Voillat, Laurent
    Joly, Bertrand
    Le Gouill, Steven
    Saad, Alain
    Cony-Makhoul, Pascale
    Vilque, Jean-Pierre
    Sanhes, Laurence
    Schmidt-Tanguy, Aline
    Bubenheim, Michael
    Houot, Roch
    Diouf, Momar
    Marolleau, Jean-Pierre
    Bene, Marie-Christine
    Martin, Antoine
    Lamy, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 104 - 110
  • [24] Results of the PROPEL Study: Phase II Trial of Pralatrexate plus Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (02): : 129 - 130
  • [25] Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study
    Reimer, Peter
    Ruediger, Thomas
    Geissinger, Eva
    Weissinger, Florian
    Nerl, Christoph
    Schmitz, Norbert
    Engert, Andreas
    Einsele, Hermann
    Mueller-Hermelink, Hans Konrad
    Wilhelm, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) : 106 - 113
  • [26] A Phase II Trial of Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; Preliminary Results
    William, Basem
    Huang, Ying
    Brammer, Jonathan
    Chung, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S359 - S360
  • [27] Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study
    Horwitz, Steven M.
    Izutsu, Koji
    Mehta-Shah, Neha
    Cordoba, Raul
    Barta, Stefan K.
    Bachy, Emmanuel
    Gritti, Giuseppe
    Jacobsen, Eric
    Kusumoto, Shigeru
    Guillermin, Yann
    Prica, Anca
    Yoon, Dok Hyun
    Domenech, Eva Domingo
    Wang, Jie
    Kim, Jin Seok
    Cwynarski, Kate
    van der Poel, Marjolein
    Inoue, Ai
    Jin, Jin
    Wu, Sutan
    Nakajima, Keiko
    Zinzani, Pier Luigi
    BLOOD, 2023, 142
  • [28] Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas
    Haverkos, Bradley M.
    Zain, Jasmine
    Kamdar, Manali K.
    Neuwelt, Alexander
    Davila, Eduardo
    Bradeen, Xander
    Bair, Steven M.
    Jasem, Jagar
    Berens, Emily
    Smith, Clayton
    Abbott, Diana
    Porcu, Pierluigi
    BLOOD, 2022, 140 : 2308 - 2309
  • [29] y Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial
    Zhang, Wei
    Su, Liping
    Liu, Lihong
    Gao, Yuhuan
    Wang, Quanshun
    Su, Hang
    Song, Yuqin
    Zhang, Huilai
    Shen, Jing
    Jing, Hongmei
    Wang, Shuye
    Cen, Xinan
    Liu, Hui
    Liu, Aichun
    Li, Zengjun
    Luo, Jianmin
    He, Jianxia
    Wang, Jingwen
    O'Connor, Owen A.
    Zhou, Daobin
    BLOOD, 2019, 134
  • [30] Valemetostat for Patients With R/R Peripheral T- Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial
    Horwitz, Steven
    Izutsu, Koji
    Mehta-Shah, Neha
    Cordoba, Raul
    Barta, Stefan
    Bachy, Emmanuel
    Gritti, Giuseppe
    Jacobsen, Eric
    Kusumoto, Shigeru
    Guillermin, Yann
    Prica, Anca
    Yoon, Dok Hyun
    Domenech, Eva Domingo
    Wang, Jie
    Kim, Jin Seok
    Cwynarski, Kate
    van der Poel, Marjolein
    Inoue, Ai
    Jin, Jin
    Wu, Sutan
    Nakajima, Keiko
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S524 - S525
12345